- Cuenoud, Bernard; Bruce, Ian; Fairhurst, Robin Alec; Beattie, David, Beta2-Adrenoceptor Agonists, Novartis A.-G., Switzerland, EP1183240B1, August 19, 2009
- Emotte, Corinne; Heudi, Olivier; Deglave, Fanny; Bonvie, Adrien; Masson, Laurence; Picard, Franck; Chaturvedi, Animesh; Majumdar, Tapan; Agarwal, Ashish; Woessner, Ralph; et al, Validation of an on-line solid-phase extraction method coupled to liquid chromatography-tandem mass spectrometry detection for the determination of Indacaterol in human serum, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences Volume: 895-896, Pages: 1-9, 2012
Frequently Asked Questions
Some impurities in Indacaterol have the potential to act as allergens and trigger allergic reactions in susceptible individuals. Controlling them reduces the risk of adverse allergic responses.
Optimization techniques, including process modifications and purification steps, help minimize the formation of impurities during the preparation of Indacaterol.
Proper storage conditions, including temperature and humidity control, help prevent degradation and impurity formation in Indacaterol.
Impurities in Indacaterol require rigorous quality control practices, ongoing stability testing, and adherence to regulatory guidelines from early development to post-marketing surveillance.
Indacaterol impurities storage should be at a controlled room temperature, within 2-8 °C.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.